This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages)(Learn how and when to remove this template message)
|Traded as||NASDAQ: DXCM|
Russell 1000 Component
|Headquarters||San Diego, California, USA|
|Kevin Sayer, CEO & President|
Number of employees
Dexcom, Inc. is a company that develops, manufactures and distributes continuous glucose monitoring systems for diabetes management. It operates internationally with headquarters in San Diego, California, United States.
DexCom's roots stem from 1967 research on implanted glucose sensors at the University of Wisconsin, and started with a focus on creating an implantable sensor that the body would not reject and that would perform for a long period of time. With over 40 patents, Dexcom's sensor technology is based on this research.
Dexcom's history includes multiple generations of sensor technology coupled with partner development agreements. In 2006, Dexcom received U.S. Food and Drug Administration (FDA) approval and launched the Dexcom STS Continuous Glucose Monitoring System. This was a three-day sensor that provided up to 288 glucose measurements every 24 hours. Dexcom received approval of the second generation product, the Seven Continuous Glucose Monitoring System in May 2007. This device improved on accuracy as well as extending usage from three to seven days of continuous wear. In 2008, Dexcom announced two consumer development agreements with Insulet Corporation and Animas Corporation as well as a development agreement with Edwards Lifesciences for a continuous glucose monitor in the intensive care unit hospital environment. During February 2009, Dexcom received approval for the SEVEN PLUS Continuous Glucose Monitor, the third generation Dexcom continuous glucose monitoring system from the FDA. This product received a CE mark in November 2009. In 2013, development to integrate with Insulet broke up. Dexcom entered a non-exclusive agreement with Tandem Diabetes Care, Inc. in 2015 to allow the integration of next generation G5 and G6 continuous glucose monitoring systems into Tandem's insulin pumps. The G5 was approved in 2016 by the FDA for use as a standalone device, while the G6 gained approval in 2018 as an integrated part of medical systems.
This section needs additional citations for verification. (December 2018) (Learn how and when to remove this template message)
Dexcom Seven Plus
The Dexcom Seven Plus is Dexcom's third generation continuous glucose monitor. It shows a new glucose reading every 5 minutes for up to seven days of wear-time. The system is made up of three components: the sensor, transmitter, and receiver. The sensor is a flexible round wire that goes just under the skin to read glucose levels, and attaches to the skin with an adhesive patch. The transmitter snaps into the sensor and wirelessly sends glucose information to the receiver every 5 minutes. The receiver displays glucose levels and trends. It is about the size and weight of a cell phone.
The system features include:
- 1-hour, 3-hour, 6-hour, 12-hour, and 24-hour period trend graphs on the receiver
- Trend arrows to show where glucose is heading
- Alerts and alarms to notify the user when glucose goes either above or below a user defined level
- Water-resistant sensor and transmitter pod (The receiver is not water-resistant)
While the receiver holds up to 30 days of data, the Dexcom Data Manager 3 (DM3) software allows data downloads from the Dexcom CGM systems to a computer. This provides users the ability to track their trends and progress over time. DM3 works with all versions of SEVEN Receivers. With the SEVEN PLUS, meal, insulin, health, and activity information entered can be reviewed later with the DM3 software. A1c values can also be entered in the software for tracking and viewing improvements.
On January 26, 2015, the FDA approved the G4 Platinum Continuous Glucose Monitoring System with Share. This model links and shares glucose data, read every 5 minutes, with cellphones via Bluetooth using an app, and can be shared with up to five others. Sensors can be worn for seven days and calibration of the sensor is required every 12 hours.
Like previous models, each sensor lasts 7 days with calibration every 12 hours. The Dexcom G5 uses the same sensor as the G4 with a different transmitter. The Dexcom G5 transmits data via bluetooth to the receiving mobile device, which can be shared with others via an app.
The Dexcom G6 was released in 2018. Unlike previous models, the new sensor lasts 10 days and does not require any regular calibration from a finger-prick.
- Republika, Česká. "About Dexcom". Dexcom.com. Retrieved December 3, 2015.
- "Insulet Corporation and DexCom Announce Development Agreement (NASDAQ:DXCM)". Investor.shareholder.com. January 7, 2008. Retrieved December 3, 2015.
- "DexCom™ Announces Joint Development Agreement with Animas Corporation". Investor.shareholder.com. June 10, 2008. Retrieved April 4, 2016.
- "Edwards Lifesciences and DexCom to Develop Continuous Glucose Monitoring Products for Hospital Market (NASDAQ:DXCM)". Investor.shareholder.com. November 10, 2008. Retrieved December 3, 2015.
- "Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems". PR Newswire. July 30, 2015. Retrieved December 3, 2015.
- "FDA authorizes first fully interoperable continuous glucose monitoring system, streamlines review pathway for similar devices" (Press release). FDA. 27 March 2018. Retrieved 27 March 2018.
- Republika, Česká (January 26, 2015). "FDA Approves Dexcom G4 Platinum Continuous Glucose Monitoring System with Share". Dexcom. Retrieved December 3, 2015.
- Official website
- Business data for Dexcom: